These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 23959396)

  • 41. HER2 expression as a potential marker for response to therapy targeted to the EGFR.
    Emlet DR; Schwartz R; Brown KA; Pollice AA; Smith CA; Shackney SE
    Br J Cancer; 2006 Apr; 94(8):1144-53. PubMed ID: 16622439
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.
    Monteiro Ide P; Madureira P; de Vasconscelos A; Pozza DH; de Mello RA
    Pharmacogenomics; 2015; 16(3):257-71. PubMed ID: 25712189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
    PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer.
    Rigakos G; Razis E; Koliou GA; Oikonomopoulos G; Tsolaki E; Sperinde J; Chrisafi S; Zarkavelis G; Pazarli E; Batistatou A; Kourea HP; Papakostas P; Bafaloukos D; Asimakopoulou NI; Res E; Kotsakis A; Pectasides D; Koutras A; Christodoulou C; Fountzilas G
    Anticancer Res; 2021 Apr; 41(4):1793-1802. PubMed ID: 33813384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.
    Duchnowska R; Sperinde J; Chenna A; Huang W; Weidler JM; Winslow J; Haddad M; Paquet A; Lie Y; Trojanowski T; Mandat T; Kowalczyk A; Czartoryska-Arłukowicz B; Radecka B; Jarosz B; Staszkiewicz R; Kalinka-Warzocha E; Chudzik M; Biernat W; Jassem J
    Neuro Oncol; 2015 Sep; 17(9):1241-9. PubMed ID: 25681308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.
    Growdon WB; Groeneweg J; Byron V; DiGloria C; Borger DR; Tambouret R; Foster R; Chenna A; Sperinde J; Winslow J; Rueda BR
    Gynecol Oncol; 2015 Apr; 137(1):160-6. PubMed ID: 25602714
    [TBL] [Abstract][Full Text] [Related]  

  • 47. p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.
    Pavlakis K; Bobos M; Batistatou A; Kotoula V; Eleftheraki AG; Stofas A; Timotheadou E; Pentheroudakis G; Psyrri A; Koutras A; Pectasides D; Papakostas P; Razis E; Christodoulou C; Kalogeras KT; Fountzilas G
    Pathol Oncol Res; 2015 Apr; 21(2):273-82. PubMed ID: 25098276
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.
    Scaltriti M; Nuciforo P; Bradbury I; Sperinde J; Agbor-Tarh D; Campbell C; Chenna A; Winslow J; Serra V; Parra JL; Prudkin L; Jimenez J; Aura C; Harbeck N; Pusztai L; Ellis C; Eidtmann H; Arribas J; Cortes J; de Azambuja E; Piccart M; Baselga J
    Clin Cancer Res; 2015 Feb; 21(3):569-76. PubMed ID: 25467182
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
    Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.
    Vassilakopoulou M; Togun T; Dafni U; Cheng H; Bordeaux J; Neumeister VM; Bobos M; Pentheroudakis G; Skarlos DV; Pectasides D; Kotoula V; Fountzilas G; Rimm DL; Psyrri A
    PLoS One; 2014; 9(6):e99131. PubMed ID: 24968015
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biology of HER2 and its importance in breast cancer.
    Yarden Y
    Oncology; 2001; 61 Suppl 2():1-13. PubMed ID: 11694782
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
    Chandarlapaty S; Scaltriti M; Angelini P; Ye Q; Guzman M; Hudis CA; Norton L; Solit DB; Arribas J; Baselga J; Rosen N
    Oncogene; 2010 Jan; 29(3):325-34. PubMed ID: 19855434
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.
    Peiró G; Ortiz-Martínez F; Gallardo A; Pérez-Balaguer A; Sánchez-Payá J; Ponce JJ; Tibau A; López-Vilaro L; Escuin D; Adrover E; Barnadas A; Lerma E
    Br J Cancer; 2014 Aug; 111(4):689-95. PubMed ID: 24937674
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
    Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
    Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
    Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.
    Brasó-Maristany F; Ferrero-Cafiero JM; Falato C; Martínez-Sáez O; Cejalvo JM; Margelí M; Tolosa P; Salvador-Bofill FJ; Cruz J; González-Farré B; Sanfeliu E; Òdena A; Serra V; Pardo F; Luna Barrera AM; Arumi M; Guerra JA; Villacampa G; Sánchez-Bayona R; Ciruelos E; Espinosa-Bravo M; Izarzugaza Y; Galván P; Matito J; Pernas S; Vidal M; Santhanagopal A; Sellami D; Esker S; Fan PD; Suto F; Vivancos A; Pascual T; Prat A; Oliveira M
    Nat Commun; 2024 Jul; 15(1):5826. PubMed ID: 38992028
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.